Scientists in Italy and Switzerland have identified a new cannabis compound with remarkable antioxidant and anti-inflammatory properties, marking another milestone in cannabinoid research.
The compound, cannabizetol (CBGD), was detailed in the September 2025 issue of the Journal of Natural Products. Researchers say the discovery adds to the growing understanding of cannabis’s therapeutic potential and highlights the complexity of its chemistry.
Key Takeaways
- Cannabizetol (CBGD) is a newly discovered cannabinoid showing strong antioxidant and skin anti-inflammatory activity.
- It belongs to a rare group called dimeric cannabinoids, in which two molecules bind together through a methylene bridge.
- CBGD showed higher biological activity than a previously known dimeric compound, cannabitwinol.
- Researchers believe there may be other undiscovered dimeric cannabinoids in cannabis with significant therapeutic potential.
- Findings suggest possible future use of CBGD in dermatological and anti-inflammatory treatments.
The Discovery of Cannabizetol (CBGD)
Cannabizetol forms when two cannabinoid molecules link via a methylene bridge, creating a dimeric compound. This is one of only four such cannabinoids identified so far in the cannabis plant.
In laboratory tests, scientists observed that CBGD displayed remarkable antioxidant activity and significantly stronger anti-inflammatory effects compared to other known cannabinoids.
“These results highlight cannabizetol as a promising bioactive metabolite with potential dermatological applications,” the authors wrote.
Testing and Biological Activity
Researchers tested CBGD on 84 inflammatory genes using an advanced PCR array to measure changes in gene expression. They focused on the NF-κB pathway, a critical molecular switch that regulates inflammation across many cell types.
After a six-hour treatment, CBGD showed a notable ability to inhibit inflammation-related activity in the tested genes. The results, researchers say, could lead to new approaches in skin care, wound healing, and inflammation management using cannabinoids.
Why Dimeric Cannabinoids Matter
Dimeric cannabinoids are considered rare because they occur when two cannabinoid units chemically link together. Scientists have identified only a handful of these structures so far, including cannabitwinol and cannabitriol, each showing unique biological properties.
According to the study’s authors, understanding these molecular pairings could open new pathways for therapeutic innovation.
“Natural dimeric compounds enable further exploration of chemical space, potentially leading to novel biological activities beyond those of their respective monomers,” they wrote.
The Bigger Scientific Picture
The discovery of CBGD adds to a rapidly expanding field of cannabinoid science. More than 100 cannabinoids have now been isolated from Cannabis sativa, but many remain poorly characterized due to the plant’s complex chemistry.
Recent breakthroughs, such as the discovery of cannabielsoxa earlier this year and new genome markers that influence cannabinoid production, show how modern research tools are accelerating discovery.
As testing technology advances, scientists are now better equipped to identify trace compounds that were once undetectable, shedding light on how cannabis produces such a wide range of biologically active molecules.
Conclusion
The identification of cannabizetol (CBGD) is another step forward in understanding the cannabis plant’s chemical diversity and potential therapeutic benefits. While more research is needed to explore its medical applications, early evidence suggests CBGD could hold promise for antioxidant and dermatological treatments in the future.
This finding reinforces the growing view among researchers that cannabis remains one of the most complex and scientifically valuable plants yet to be fully understood.
This article is based on publicly available legislative records, court filings, industry reports, and published research as of the publication date. Cannabis laws and regulations change frequently — verify current rules with your state’s regulatory agency.
